These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6821809)

  • 21. Surgical adjuvant therapy for malignant melanoma.
    Pinsky CM; Oettgen HF
    Surg Clin North Am; 1981 Dec; 61(6):1259-66. PubMed ID: 7031933
    [No Abstract]   [Full Text] [Related]  

  • 22. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
    Thatcher N; Hashmi K; Chang J; Swindell R; Crowther D
    Cancer; 1980 Sep; 46(6):1378-82. PubMed ID: 7417939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of BCG and C. parvum treatment on human melanoma xenografts.
    Garrett AJ; Reeson DE; Osborn TW; Boulger LR
    Dev Biol Stand; 1977 Apr 13-15; 38():363-8. PubMed ID: 608525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
    Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
    Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
    Fisher RI; Terry WD; Hodes RJ; Rosenberg SA; Makuch R; Gordon HG; Fisher SG
    Surg Clin North Am; 1981 Dec; 61(6):1267-77. PubMed ID: 7031934
    [No Abstract]   [Full Text] [Related]  

  • 30. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM; Hutchins GM
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
    Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
    Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
    Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
    Castel T; Estapé J; Viñolas N; Mascaró JM; Castro J; Vilalta A; Gratacós R; Daniels M; Palou J; Grau JJ
    Dermatologica; 1991; 183(1):25-30. PubMed ID: 1769411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
    Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
    Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
    Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Deutschmann KE; Peter HH; Schultheis W; Deicher H
    Tumori; 1977; 63(3):303-7. PubMed ID: 898298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
    Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
    Knost JA; Reynolds V; Greco FA; Oldham RK
    J Surg Oncol; 1982 Mar; 19(3):165-70. PubMed ID: 7040820
    [No Abstract]   [Full Text] [Related]  

  • 40. [Intratumor BCG immunotherapy of advanced malignant melanoma].
    Jassem J
    Nowotwory; 1981; 31(1):67-70. PubMed ID: 7290998
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.